Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Legend Biotech's enterprise value is $3,143 Mil.
Legend Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-175 Mil. Therefore, Legend Biotech's EV-to-EBITDA for today is -17.93.
The historical rank and industry rank for Legend Biotech's EV-to-EBITDA or its related term are showing as below:
LEGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.59 Med: -19.21 Max: -8.41
Current: -17.93
During the past 8 years, the highest EV-to-EBITDA of Legend Biotech was -8.41. The lowest was -56.59. And the median was -19.21.
LEGN's EV-to-EBITDA is ranked worse than 100% of 416
companies
in the Biotechnology industry
Industry Median: 11.905
vs LEGN: -17.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Legend Biotech's PE Ratio (TTM) for today is calculated as:
Legend Biotech's share price for today is $18.55.
Legend Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Legend Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Legend Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Legend Biotech's EV-to-EBITDA falls into.
Legend Biotech's current Enterprise Value is $3,143 Mil.
Legend Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-175 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech (LEGN) has a EV-to-EBITDA of -17.93 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Legend Biotech. According to the industry distribution chart, Legend Biotech ranks #999999 out of 416 companies in the Biotechnology industry.
Is Legend Biotech's EV-to-EBITDA too high?
Legend Biotech's current EV-to-EBITDA is -17.93. Based on the distribution chart, Legend Biotech ranks #999999 out of 416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Legend Biotech has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's EV-to-EBITDA compare to TNGX and ACAD?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #999999 out of 416 companies for EV-to-EBITDA. This places Legend Biotech in the lower half of its industry. The industry median EV-to-EBITDA is 11.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.91, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Legend Biotech. For the Biotechnology industry, the median EV-to-EBITDA is 11.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Legend Biotech's current EV-to-EBITDA is -17.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $101.53, compared to a current price of $18.55 — trading 81.7% below its estimated fair value. The current EV-to-EBITDA is -17.93. Legend Biotech's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Legend Biotech (LEGN), the current EV-to-EBITDA is -17.93 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $18.55 is trading 81.7% below its estimated GF Value™ of $101.53.
GuruFocus considers Legend Biotech to be Possible Value Trap.
Key valuation signals for LEGN:
EV-to-EBITDA: -17.93
GF Value™: $101.53 vs. price of $18.55 (81.7% below fair value)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
74GF Score
Get the complete analysis for LEGN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
